A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

Background: * Human papillomavirus (HPV)+ oropharyngeal cancer is an increasingly common type of cancer that frequently affects young patients. * Although the prognosis of early-stage cancer is favorable, the treatments can result in significant life-long morbidity. * Neoadjuvant therapy is an active area of investigation. The goal of neoadjuvant therapy in this setting is to reduce the risk of disease recurrence and permit the study of de- intensified definitive treatment of early-stage disease. * E7 TCR T cells have demonstrated safety and clinical activity in treatment-refractory metastatic HPV+ cancers. Objectives: \- To determine the feasibility of intratumoral injection of E7 TCR T cells as neoadjuvant therapy for borderline resectable and unresectable stage I HPV+ oropharyngeal cancer. Eligibility: \- Patients greater than or equal to 18 years of age with borderline resectable or unresectable stage I HPV+ oropharyngeal cancer. Design: * This is a phase II, single arm, feasibility study of neoadjuvant E7 TCR T cell therapy for borderline resectable and unresectable stage I HPV+ oropharyngeal cancer. * Patients will receive intratumoral injection of E7 TCR T cells into the primary tumor and involved regional lymph nodes * Patients will not receive a conditioning chemotherapy regimen or systemic aldesleukin * Patients will be referred for definitive standard of care therapy following completion of protocol therapy